RHOBTB2 and breast carcinoma: Moreover, deletions and loss-of-function variants in RHOBTB2 were detected in nearly 10% of breast cancer samples, suggesting that these variants may lead to the loss of tumor-suppressor activity and the initiation of cancerous tumor formation (Figure 3) (33).